Unveiling Polymorphism: Exploring its Role in Symptomatic COVID-19 Susceptibility

Vihaan D. Gupta^*
*Correspondence: Vihaan D. Gupta, Department of Infectious Diseases, SCB Medical College & Hospital, Cuttack, India, Email:

Keywords

Polymorphism • Genetic variation • COVID-19 • Public Health

Introduction

As the world grapples with the COVID-19 pandemic, researchers and healthcare professionals are tirelessly working to decipher the complexities of the virus and its impact on human health. Among the myriad factors influencing an individual's response to the virus, genetic polymorphism stands out as a significant determinant of susceptibility to symptomatic COVID-19 [1]. Polymorphism, the occurrence of multiple forms of a gene within a population, plays a pivotal role in shaping an individual's immune response and susceptibility to infectious diseases. In this article, we explore the concept of polymorphism and its implications for understanding symptomatic susceptibility to COVID-19.

Literature Review

Polymorphism arises from genetic variations within a population, where different alleles of a gene can lead to distinct phenotypic traits. These variations can range from single nucleotide changes to large-scale structural alterations in the genome. The significance of polymorphism lies in its role in evolutionary adaptation and the diversity it confers within populations. Recent studies have shed light on the influence of genetic polymorphism on COVID-19 susceptibility and severity. Certain genetic variants have been associated with an increased risk of developing severe symptoms upon infection with the SARS-CoV-2 virus. For example, variations in genes encoding key components of the immune system, such as the ACE2 receptor and genes related to cytokine production, have been implicated in modulating the host response to the virus [2].

The ACE2 receptor serves as the primary entry point for SARS-CoV-2 into human cells. Polymorphisms in the ACE2 gene may alter the binding affinity of the receptor for the virus, affecting viral entry and subsequent infection. Variants that enhance ACE2 expression or binding affinity could potentially increase susceptibility to COVID-19, whereas those that reduce ACE2 expression or binding may confer protection against severe disease.

Discussion

Cytokines play a crucial role in regulating the immune response to viral infections. Polymorphisms in genes encoding cytokines or their receptors can influence the magnitude and duration of the inflammatory response triggered by SARS-CoV-2. Certain variants may predispose individuals to an exaggerated cytokine storm, contributing to the development of severe COVID-19 symptoms such as Acute Respiratory Distress Syndrome (ARDS) and multi-organ failure. The presence of genetic polymorphism accounts for the observed heterogeneity in symptomatic susceptibility among COVID-19 patients [3]. While some individuals remain asymptomatic or experience mild symptoms, others develop severe illness requiring hospitalization and intensive care. Genetic factors, including polymorphisms, interact with environmental and demographic variables to determine an individual's risk profile for symptomatic COVID-19.

Understanding the role of polymorphism in COVID-19 susceptibility has profound implications for public health interventions. Genetic screening and profiling could help identify individuals at higher risk of developing severe symptoms and guide targeted preventive measures and treatment strategies. Moreover, knowledge of genetic polymorphism can inform vaccine development efforts, enabling the design of vaccines that elicit optimal immune responses across diverse populations. Moving forward, further research into the role of polymorphism in COVID-19 susceptibility is warranted to address remaining questions and uncertainties. Longitudinal studies tracking the progression of COVID-19 in individuals with specific genetic variants can provide valuable insights into the mechanisms underlying polymorphism-mediated susceptibility. Additionally, large-scale genomic studies encompassing diverse populations are needed to identify novel genetic markers associated with symptomatic COVID-19.

While the focus of this article has been on the role of polymorphism in COVID-19 susceptibility, it's important to recognize that genetic variation influences susceptibility to a wide range of infectious diseases. Polymorphism in genes encoding immune receptors, pathogen recognition molecules, and cytokines can impact an individual's ability to mount an effective immune response against diverse pathogens, including bacteria, viruses, and parasites. For example, polymorphisms in the HLA (Human Leukocyte Antigen) genes, which play a central role in presenting antigens to T cells, have been implicated in susceptibility to infectious diseases such as HIV, hepatitis B and C, malaria, and tuberculosis. Understanding how genetic polymorphism influences susceptibility to various pathogens can inform the development of targeted interventions and vaccines tailored to specific populations.

Polymorphism not only influences individual susceptibility to disease but also contributes to genetic diversity within populations. Natural selection acts on genetic variation, favouring alleles that confer a fitness advantage in specific environments or under selective pressures such as infectious diseases. As a result, polymorphism is a driving force behind evolutionary adaptation and population diversity [4]. Studying patterns of polymorphism across populations provides insights into human evolutionary history, migration patterns, and adaptation to different environments. Population genetics analyses, coupled with advances in genomic sequencing technologies, have revolutionized our understanding of human genetic diversity and the evolutionary forces shaping it.

The era of personalized medicine leverages genetic information to tailor medical interventions to individual patients, maximizing efficacy and minimizing adverse effects. Genetic testing for polymorphisms associated with drug metabolism, efficacy, and toxicity allows healthcare providers to prescribe medications at optimal doses and select treatments tailored to an individual's genetic profile. In the realm of public health, precision medicine approaches aim to target interventions to subpopulations with the greatest need or likelihood of benefit. Incorporating genetic data, along with other omics data and environmental factors, into predictive models enables more accurate risk assessment and targeted interventions for disease prevention and management.

Despite the promise of polymorphism in advancing personalized medicine and public health, several challenges remain. Ethical considerations surrounding genetic privacy, informed consent, and the potential for discrimination must be carefully addressed to ensure the responsible use of genetic information. Additionally, disparities in access to genetic testing and healthcare services pose barriers to realizing the full potential of precision medicine. Efforts to address healthcare inequities and promote health literacy are essential for ensuring equitable access to the benefits of genomic medicine [5]. Moreover, the complex nature of gene-environment interactions and the polygenic basis of many diseases pose challenges for predicting disease risk and treatment response based solely on genetic data. Integration of multiomics data and advanced computational methods will be crucial for unraveling the intricate networks underlying disease susceptibility and designing targeted interventions.

Polymorphism is a fundamental aspect of human genetic diversity with profound implications for health and disease. In the context of infectious diseases like COVID-19, understanding how genetic variation influences susceptibility and host response is essential for devising effective prevention and treatment strategies. As genomic technologies continue to advance and our understanding of genetic variation expands, the promise of personalized medicine and precision public health grows ever closer to realization. By harnessing the power of polymorphism, we can unlock new insights into human biology, disease susceptibility, and population health, paving the way for a healthier and more equitable future [6].

Integration of genomic data with clinical information holds promise for the development of predictive models that can accurately assess an individual's risk of developing severe COVID-19 based on their genetic profile. Such models could aid healthcare professionals in triaging patients, allocating resources, and implementing targeted interventions to mitigate the impact of the pandemic. Furthermore, the emergence of new SARS-CoV-2 variants underscores the importance of ongoing surveillance and adaptation of public health strategies. Investigating how genetic polymorphism influences susceptibility to variant strains can inform vaccine design and deployment strategies, ensuring broad and equitable protection across populations.

Conclusion

Genetic polymorphism represents a critical determinant of symptomatic susceptibility to COVID-19, shaping the variability in disease presentation and severity observed among affected individuals. By unraveling the intricate interplay between genetic variation and viral infection, researchers can pave the way for more personalized approaches to COVID-19 prevention, diagnosis, and treatment. Moving forward continued research into polymorphism and its implications for infectious disease susceptibility will be essential for mitigating the impact of pandemics on global health.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Igarashi, Ataru, Emi Hirose, Yasuhiro Kobayashi and Naohiro Yonemoto, et al. "Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan." Expert Rev Vaccines20 (2021): 1153-1165.

   Google Scholar, Crossref, Indexed at

2. Lakdawalla, Darius N., Jalpa A. Doshi, Louis P. Garrison Jr. and Charles E. Phelps, et al. "Defining elements of value in health care—a health economics approach: An ISPOR Special Task Force report [3]." Value Health 21 (2018): 131-139.

   Google Scholar, Crossref, Indexed at

3. Bowe, Benjamin, Yan Xie and Ziyad Al-Aly. "Postacute sequelae of COVID-19 at 2 years." Nat Med 29 (2023): 2347-2357.

   Google Scholar, Crossref, Indexed at

4. Alanazi, Saad Awadh, M. M. Kamruzzaman, Madallah Alruwaili and Nasser Alshammari, et al. "Measuring and preventing COVID-19 using the SIR model and machine learning in smart health care." J Health Eng 2020 (2020).

   Google Scholar, Crossref, Indexed at

5. Hussein, Haval I., Abdulhakeem O. Mohammed, Masoud M. Hassan and Ramadhan J. Mstafa. "Lightweight deep CNN-based models for early detection of COVID-19 patients from chest X-ray images." Exp Syst Appl 223 (2023): 119900.

   Google Scholar, Crossref, Indexed at

6. Rahimi, Iman, Fang Chen and Amir H. Gandomi. "A review on COVID-19 forecasting models." Neural Comput Appl 35 (2023): 23671-23681.

   Google Scholar, Crossref, Indexed at